Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $97.4K invested in Evoke Pharma in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.02% less ownership
Funds ownership: 0.17% → 0.15% (-0.02%)
9% less funds holding
Funds holding: 11 → 10 (-1)
26% less capital invested
Capital invested by funds: $131K → $97.4K (-$33.7K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.91K |
| 2 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$21K |
| 2 |
LC
Lindbrook Capital
Calabasas,
California
|
-$158 |
| 3 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
-$153 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $49.3K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $34.3K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $9.21K | +$2.91K | +133 | +40% |
|
4
BlackRock
New York
| $2.43K | – | – | – |
|
5
UBS Group
Zurich,
Switzerland
| $1.83K | – | – | – |
|
|
NA
6
NewEdge Advisors
New Orleans,
Louisiana
| $343 | – | – | – |
|
|
CWP
7
Concord Wealth Partners
Abingdon,
Virginia
| $51 | -$153 | -7 | -70% |
|
8
Wells Fargo
San Francisco,
California
| $28 | – | – | – |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $8 | – | – | – |
|
|
10
Renaissance Technologies
New York
| – | -$21K | -932 | Closed |
|
|
LC
11
Lindbrook Capital
Calabasas,
California
| – | -$158 | -7 | Closed |
|
|
12
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$22 | +1 | New |
|
EVOK Hedge Fund Activity: Q2 2023 in Review
10 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2023, worth a combined $97.4K — down 26% from $131K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EVOK and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.91K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $21K sold.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q2 2023, down from 11 in Q1 2023.
- Funds reported $97.4K of Evoke Pharma stock for Q2 2023, down 26% quarter-over-quarter.
- 1 fund opened new Evoke Pharma positions in Q2 2023 and 2 closed out, a net change of -1 holder.
- The largest Evoke Pharma buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $2.91K added.
- The largest Evoke Pharma seller in Q2 2023 was Renaissance Technologies, an estimated $21K sold.
Based on aggregated 13F filings for Q2 2023.